{"schema_version":"secwatch.filing_event.v1","accession":"0001213900-24-027960","form_type":"8-K","ticker":"INMB","cik":"0001711754","company_name":"Inmune Bio, Inc.","filed_at":"2024-03-29T23:59:59+00:00","discovered_at":"2026-05-14T18:03:25.208033+00:00","generated_at":"2026-06-04T05:26:08.750682+00:00","sec_items":["2.02","8.01","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.55,"calibrated_materiality_score":0.55,"confidence":"high","headline":"INmune Bio reports FY2023 net loss of $30.0M; pipeline updates for XPro, INKmune","bullets":["Net loss for FY2023 was $30.0M, up from $27.3M in FY2022; R&D spend rose to $20.3M.","Cash and equivalents at Dec 31, 2023: $35.8M; shares outstanding ~18.0M as of Mar 28, 2024.","XPro AD02 Alzheimer's trial on track for mid-2024 enrollment completion; top-line data ~6 months later.","Phase I/II INKmune mCRPC trial enrolled first patient Dec 2023; cohort 2 to open after DSMC review in mid-April.","Company winding down AML program to focus on prostate cancer and other solid tumors."],"urls":{"canonical":"https://secwatch.observer/filing/0001213900-24-027960","json":"https://secwatch.observer/filing/0001213900-24-027960.json","markdown":"https://secwatch.observer/filing/0001213900-24-027960.md","text":"https://secwatch.observer/filing/0001213900-24-027960.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1711754/000121390024027960/0001213900-24-027960-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1711754/000121390024027960/ea0202918-8k_inmune.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-04T05:26:08.750682+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"97af067613e88f4e015ea8c8d946e35b132011df","claim":"Inmune Bio, Inc. reported the year ended December 31, 2023 results: net income approximately $30.0 million.","evidence_excerpt":"Net loss attributable to common stockholders for the year ended December 31, 2023, was approximately $30.0 million, compared to approximately $27.3 million during the year ended December 31, 2022.","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1711754/000121390024027960/0001213900-24-027960-index.htm","confidence":0.9,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the year ended December 31, 2023"},{"label":"Net income","value":"approximately $30.0 million"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}